Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Steven Kelly, President and CEO, will represent the company at the conference on Tuesday, February 11 at 4:40 pm ET.

The presentation will be accessible via audio webcast through the Company's Investor Events section on their Investor Relations webpage, with -time archive availability following the event.

News Market Reaction – CARM

+15.95%

+15.95% Session move

In the trading session that priced this news, CARM gained 15.95%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35^th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET.

An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

About Carisma

Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.

Investors:
Shveta Dighe
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367990.html

SOURCE Carisma Therapeutics Inc.

FAQ

When is Carisma Therapeutics (CARM) presenting at the Oppenheimer Healthcare Conference 2025?

Carisma Therapeutics (CARM) will present at the Oppenheimer Healthcare Conference on Tuesday, February 11, 2025, at 4:40 pm ET.

How can investors access Carisma Therapeutics' (CARM) Oppenheimer Conference presentation?

Investors can access the audio webcast through the Investor Events section of Carisma Therapeutics' Investor Relations webpage. The presentation will be archived for a time after the event.

Who will represent CARM at the 2025 Oppenheimer Healthcare Conference?

Steven Kelly, President and Chief Executive Officer of Carisma Therapeutics, will represent CARM at the conference.

What type of therapeutics does Carisma (CARM) specialize in?

Carisma Therapeutics specializes in macrophage-focused therapeutics, positioning itself as a leader in this field.